What is the catalog number for V-9302?

The catalog number for V-9302 is HY-112683.

What sizes are available for V-9302?

V-9302 is available in the following size(s): 5 mg, 10 mg, 25 mg, 50 mg, 100 mg.

How many pack sizes does V-9302 come in?

V-9302 is available in 5 different pack sizes.

V-9302 is currently made to order / not held in immediate stock. Contact us for lead time.

Who manufactures V-9302?

V-9302 is manufactured by QuantiMol.

What is the estimated delivery time for V-9302?

Estimated delivery time for V-9302 is approximately 15 business day(s), depending on your location.

Where can I find the safety data sheet (SDS/MSDS) for V-9302?

The safety data sheet for V-9302 is available here: http://file.medchemexpress.com/batch_PDF/HY-112683/V-9302-SDS-MedChemExpress.pdf.

V-9302

V-9302 is a competitive antagonist of transmembrane glutamine flux. V-9302 selectively and potently targets the amino acid transporter ASCT2 (SLC1A5) not ASCT1. V-9302 inhibits ASCT2-mediated glutamine uptake (IC50=9.6 μM) in HEK-293 cells[1].

Product Specifications

CAS Number

1855871-76-9

UNSPSC

12352005

Target

ASCT

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/v-9302.html

Purity

99.46

Solubility

DMSO : 25 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : < 0.1 mg/mL (ultrasonic)

Smiles

O=C(O)[C@@H](N)CCN(CC1=CC=CC=C1OCC2=CC=CC(C)=C2)CC3=CC=CC=C3OCC4=CC=CC(C)=C4

Molecular Formula

C34H38N2O4

Molecular Weight

538.68

References & Citations

[1]Schulte ML, et al. Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacyin preclinical models. Nat Med. 2018 Feb;24 (2) :194-202.|[2]Jin H, et al. A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. Elife. 2020;9:e56749. Published 2020 Oct 5.|[3]Edwards DN, et al. Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2021;131 (4) :e140100.